FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Ferlay J, Soerjomataram I, Dikshit R et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136(5), e359–e386 (2015).
  Medline CASGoogle Scholar
• 2 Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol. Med. 14(1), 9–32 (2017).
  Medline CASGoogle Scholar
• 3 Lacey JV, Sherman ME. Ovarian neoplasia. In: Robboy's Pathology of the Female Reproductive Tract. Robboy SL, Mutter GL, Prat J (Eds). Churchill Livingstone, Elsevier, Oxford, UK, 601 (2009).
  Google Scholar
• 4 Desai A, Xu J, Aysola K et al. Epithelial ovarian cancer: an overview. World J. Transl. Med. 3(1), 1–8 (2014).
  MedlineGoogle Scholar
• 5 Davis A, Tinker AV, Friedlander M. ‘Platinum resistant’ ovarian cancer: what is it, who to treat and how to measure benefit? Gynecol. Oncol. 133(3), 624–631 (2014).
  Medline CASGoogle Scholar
• 6 Markman M, Bookman MA. Second-line treatment of ovarian cancer. Oncologist 5(1), 26–35 (2000).
  Medline CASGoogle Scholar
• 7 Luvero D, Milani A, Ledermann JA. Treatment options in recurrent ovarian cancer: latest evidence and clinical potential. Ther. Adv. Med. Oncol. 6(5), 229–239 (2014).
  Medline CASGoogle Scholar
• 8 Pujade-Lauraine E, Hilpert F, Weber B et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized Phase III trial. J. Clin. Oncol. 32(13), 1302–1308 (2014). •• Pivotal Phase III trial results that resulted in approval of bevacizumab for the treatment of ovarian cancer.
  Medline CASGoogle Scholar
• 9 Poveda AM, Selle F, Hilpert F et al. Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: analysis by chemotherapy cohort of the randomized Phase III AURELIA trial. J. Clin. Oncol. 33(32), 3836–3838 (2015).
  Medline CASGoogle Scholar
• 10 Pistollato F, Calderon Iglesias R, Ruiz R et al. The use of natural compounds for the targeting and chemoprevention of ovarian cancer. Cancer Lett. 411, 191–200 (2017).
  Medline CASGoogle Scholar
• 11 Liu J, Matulonis UA. New strategies in ovarian cancer: translating the molecular complexity of ovarian cancer into treatment advances. Clin. Cancer Res. 20(20), 5150–5156 (2014).
  Medline CASGoogle Scholar
• 12 Della Pepa C, Tonini G, Pisano C et al. Ovarian cancer standard of care: are there real alternatives? Chin. J. Cancer 34(1), 17–27 (2015).
  Medline CASGoogle Scholar
• 13 Colombo N, Conte PF, Pignata S, Raspagliesi F, Scambia G. Bevacizumab in ovarian cancer: focus on clinical data and future perspectives. Crit. Rev. Oncol. Hematol. 97, 335–348 (2016).
  MedlineGoogle Scholar
• 14 Konecny GE, Kristeleit RS. PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions. Br. J. Cancer 115(10), 1157–1173 (2016).
  Medline CASGoogle Scholar
• 15 Vergote IB, Marth C, Coleman RL. Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications. Cancer Metastasis Rev. 34(1), 41–52 (2015). • Summarizes role of folate receptor in ovarian cancer, providing a rationale for targeting this receptor in the development of new therapeutic agents.
  Medline CASGoogle Scholar
• 16 Choi SW, Mason JB. Folate and carcinogenesis: an integrated scheme. J. Nutr. 130(2), 129–132 (2000).
  Medline CASGoogle Scholar
• 17 Kalli KR, Oberg AL, Keeney GL et al. Folate receptor α as a tumor target in epithelial ovarian cancer. Gynecol. Oncol. 108(3), 619–626 (2008).
  Medline CASGoogle Scholar
• 18 Markert S, Lassmann S, Gabriel B et al. Alpha-folate receptor expression in epithelial ovarian carcinoma and non-neoplastic ovarian tissue. Anticancer Res. 28(6A), 3567–3572 (2008).
  MedlineGoogle Scholar
• 19 O'Shannessy DJ, Somers EB, Smale R, Fu YS. Expression of folate receptor-α (FRA) in gynecologic malignancies and its relationship to the tumor type. Int. J. Gynecol. Pathol. 32(3), 258–268 (2013).
  MedlineGoogle Scholar
• 20 Toffoli G, Russo A, Gallo A et al. Expression of folate binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancer. Int. J. Cancer 79(2), 121–126 (1998).
  Medline CASGoogle Scholar
• 21 Marchetti C, Palaia I, Giorgini M et al. Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review. Onco Targets Ther. 7, 1223–1236 (2014).
  Medline CASGoogle Scholar
• 22 Assaraf YG, Leamon CP, Reddy JA. The folate receptor as a rational therapeutic target for personalized cancer treatment. Drug Resist. Updat. 17(4–6), 89–95 (2014).
  MedlineGoogle Scholar
• 23 Ledermann JA, Canevari S, Thigpen T. Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments. Ann. Oncol. 26(10), 2034–2043 (2015).
  Medline CASGoogle Scholar
• 24 Vergote I, Armstrong D, Scambia G et al. A randomized, double-blind, placebo-controlled, Phase III study to assess efficacy and safety of weekly farletuzumab in combination with carboplatin and taxane in patients with ovarian cancer in first platinum-sensitive relapse. J. Clin. Oncol. 34(19), 2271–2278 (2016).
  Medline CASGoogle Scholar
• 25 Levin J. Merck and endocyte announce independent DSMB recommends vintafolide PROCEED Phase III trial be stopped for futility following interim analysis. FierceBiotech (2014). www.fiercebiotech.com/biotech/merck-and-endocyte-announce-independent-dsmb-recommends-vintafolide-proceed-phase-3-trial.
  Google Scholar
• 26 Chari RV, Miller ML, Widdison WC. Antibody–drug conjugates: an emerging concept in cancer therapy. Angew. Chem. Int. Ed. Engl. 53(15), 3796–3827 (2014).
  Medline CASGoogle Scholar
• 27 Parslow AC, Parakh S, Lee FT, Gan HK, Scott AM. Antibody–drug conjugates for cancer therapy. Biomedicines 4(3), e254–e262 (2016).
  Google Scholar
• 28 Thomas A, Teicher BA, Hassan R. Antibody–drug conjugates for cancer therapy. Lancet Oncol. 17(6), e254–e262 (2016).
  Medline CASGoogle Scholar
• 29 Lambert JM, Morris CQ. Antibody–drug conjugates (ADCs) for personalized treatment of solid tumors: a review. Adv. Ther. 34(5), 1015–1035 (2017).
  Medline CASGoogle Scholar
• 30 Lambert JM, Berkenblit A. Antibody–drug conjugates for cancer treatment. Annu. Rev. Med. 17(6), e254–e262 (2017). • Comprehensive review of the current status of antibody–drug conjugates undergoing advanced clinical testing.
  Google Scholar
• 31 Gunderson CC, Moore KM. Mirvetuximab soravtansine. Folate receptor α (FR-α)-targeting antibody drug conjugate, treatment of epithelial ovarian cancer. Neoplasia 18(12), 775–784 (2016).
  MedlineGoogle Scholar
• 32 Oroudjev E, Lopus M, Wilson L et al. Maytansinoid–antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability. Mol. Cancer Ther. 9(10), 2700–2713 (2010).
  Medline CASGoogle Scholar
• 33 Goldmacher VS, Audette CA, Guan Y et al. High-affinity accumulation of a maytansinoid in cells via weak tubulin interaction. PLoS ONE 10(2), e0117523 (2015).
  MedlineGoogle Scholar
• 34 Kovtun YV, Audette CA, Ye Y et al. Antibody–drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res. 66(6), 3214–3221 (2006).
  Medline CASGoogle Scholar
• 35 Ab O, Whiteman KR, Bartle LM et al. IMGN853, a folate receptor-α (FR-α)-targeting antibody–drug conjugate, exhibits potent targeted antitumor activity against FR-α-expressing tumors. Mol. Cancer Ther. 14(7), 1605–1613 (2015). • Preclinical development and characterization of mirvetuximab soravtansine.
  Medline CASGoogle Scholar
• 36 Ponte JF, Ab O, Lanieri L et al. Mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody–drug conjugate, potentiates the activity of standard of care therapeutics in ovarian cancer models. Neoplasia 18(12), 775–784 (2016).
  Medline CASGoogle Scholar
• 37 Moore KN, Borghaei H, O'Malley DM et al. Phase I dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody–drug conjugate, in patients with solid tumors. Cancer 123(16), 3080–3087 (2017).
  Medline CASGoogle Scholar
• 38 Eaton JS, Miller PE, Mannis MJ, Murphy CJ. Ocular adverse events associated with antibody–drug conjugates in human clinical trials. J. Ocul. Pharmacol. Ther. 31(10), 589–604 (2015).
  Medline CASGoogle Scholar
• 39 Martin LP, Konner JA, Moore KN et al. Characterization of folate receptor α (FR-α) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: a Phase I expansion study of the FR-α-targeting antibody–drug conjugate mirvetuximab soravtansine. Gynecol. Oncol. 147(2), 402–407 (2017).
  Medline CASGoogle Scholar
• 40 Moore KN, Martin LP, O'Malley DM et al. Safety and activity of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Phase I expansion study. J. Clin. Oncol. 35(10), 1112–1118 (2017). •• Findings of a Phase I expansion cohort study indicating that mirvetuximab soravtansine is clinically active in patients with platinum-resistant epithelial ovarian cancer.
  Medline CASGoogle Scholar
• 41 Moore KN, Matulonis UA, O'Malley DM et al. Mirvetuximab soravtansine (IMGN853), a folate alpha (FR-α)-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian caner (EOC) patients (pts): activity and safety analyses in Phase I pooled expansion cohorts. J. Clin. Oncol. 35(Suppl.), Abstract 5547 (2017).
  Google Scholar
• 42 Marupudi NI, Han JE, Li KW, Renard VM, Tyler BM, Brem H. Paclitaxel: a review of adverse toxicities and novel delivery strategies. Expert Opin. Drug Saf. 6(5), 609–621 (2007).
  Medline CASGoogle Scholar
• 43 Rosenberg P, Andersson H, Boman K et al. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncol. 41(5), 418–424 (2002).
  Medline CASGoogle Scholar
• 44 Markman M, Hall J, Spitz D et al. Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. J. Clin. Oncol. 20(9), 2365–2369 (2002).
  Medline CASGoogle Scholar
• 45 Gynecologic Oncology Group, Markman M, Blessing J et al. Phase II trial of weekly paclitaxel (80 mg/m²) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol. Oncol. 101(3), 436–440 (2006).
  MedlineGoogle Scholar
• 46 Baird RD, Tan DS, Kaye SB. Weekly paclitaxel in the treatment of recurrent ovarian cancer. Nat. Rev. Clin. Oncol. 7(10), 575–582 (2010).
  Medline CASGoogle Scholar
• 47 Markman M. Pegylated liposomal doxorubicin: appraisal of its current role in the management of epithelial ovarian cancer. Cancer Manag. Res. 3, 219–225 (2011).
  Medline CASGoogle Scholar
• 48 Markman M, Kennedy A, Webster K, Peterson G, Kulp B, Belinson J. Phase II trial of liposomal doxorubicin (40 mg/m(²)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. Gynecol. Oncol. 78(3 Pt 1), 369–372 (2000).
  Medline CASGoogle Scholar
• 49 Wilailak S, Linasmita V. A study of pegylated liposomal doxorubicin in platinum-refractory epithelial ovarian cancer. Oncology 67(3–4), 183–186 (2004).
  Medline CASGoogle Scholar
• 50 Nakayama M, Kobayashi H, Takahara T, Nishimura Y, Fukushima K, Yoshizawa K. A comparison of overall survival with 40 and 50 mg/m² pegylated liposomal doxorubicin treatment in patients with recurrent epithelial ovarian cancer: propensity score-matched analysis of real-world data. Gynecol. Oncol. 143(2), 246–251 (2016).
  Medline CASGoogle Scholar
• 51 Sehouli J, Oskay-Ozcelik G. Current role and future aspects of topotecan in relapsed ovarian cancer. Curr. Med. Res. Opin. 25(3), 639–651 (2009).
  Medline CASGoogle Scholar
• 52 Sehouli J, Stengel D, Harter P et al. Topotecan weekly versus conventional 5-day schedule in patients with platinum-resistant ovarian cancer: a randomized multicenter Phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J. Clin. Oncol. 29(2), 242–248 (2011).
  Medline CASGoogle Scholar